ADAP Advocacy has launched a national advocacy campaign targeting reforms in the 340B Drug Pricing Program, questioning the program's accountability and potential financial risks. The campaign, titled '340B Too Big To Fail', aims to draw attention to the lack of meaningful oversight in the nation's second-largest federally sponsored drug program.
Brandon M. Macsata, CEO of ADAP Advocacy, compared the current state of the 340B program to the financial market conditions preceding the 2007-2008 economic crisis. The organization's commercial, airing in the Washington, DC metropolitan area, challenges the program's transparency standards, particularly among large hospital systems.
The campaign will explore critical issues including declining hospital charity care, increasing healthcare executive compensation, and the growing burden of patient medical debt. By highlighting these concerns, ADAP Advocacy seeks to prompt congressional and public scrutiny of the drug pricing program's current structure.
Running through the end of the year, the advocacy effort represents a significant challenge to the existing framework of the 340B Drug Pricing Program, potentially signaling a broader conversation about healthcare pricing and institutional accountability.
